New clinical study at the Martini-Klinik to improve care for prostate cancer patients

Bactiguard starts a new clinical trial that aims to reduce the risk of catheter associated urinary tract infections and the use of antibiotics in patients undergoing prostate cancer surgery in the well renowned Martini-Klinik of the University Medical Center Hamburg-Eppendorf.

“In our never ending quest to improve the quality of life for our patients, we are continuously evaluating different ways that could improve patient outcomes and the quality of care. We are therefore very exicted about this study, in particular the possibility to reduce the use of antibiotics”, says Dr. Uwe Michl, Chief Physician at Martini-Klinik.

The Martini-Klinik is specialized in prostate cancer diagnosis and treatment and is today the number one prostate cancer center in the world in terms of number of radical prostatectomies annually - with over 2200 operations 2015. The institute is focused on providing value based healthcare, where quality of life aspects for patients are at the centre of attention.

Patients who have undergone prostate cancer operations typically need a Foley catheter for a period of about 1-2 weeks after the surgery. The use of Foley catheters is well know to cause catheter assocated urinary tract infections (CAUTI) that require antibiotics.

“We are very proud to work together with the world leading and well renowed Martini-Klinik in this important clinical study. Reducing the risk of infections requiring antibiotics is of paramount importance, particularly in light of increasing antimicrobial resistance. We believe that the use of Bactiguard technology can decrease the current need for antibiotics for this group of patients”, says Johan Rugfelt, COO at Bactiguard.

The purpose of the study is to evaluate the effect of Bactiguard Infection Protection urinary catheters (BIP Foley Catheters) in the reduction of microbial growth in urine, catheter-associated urinary tract infections and the need for antibiotics in 100 patients undergoing open surgery for prostate cancer. The patients will be randomized into either receiving a Bactiguard catheter or a standard uncoated catheter. The patients will be followed during the entire catheterization time and one week after the catheter has been removed. Quality of life aspects will be recorded along with the clinical outcome. The study is expected to continue for a period of 6-9 months.

For further information, please contact:

Johan Rugfelt, COO at Bactiguard +46708724739

About Bactiguard
Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of Foley catheters, central venous catheters and endotracheal tubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 60 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

About Martini Klinik
The Martini-Klinik is a private clinic of the University Medical Center Hamburg-Eppendorf (UKE). We are, in terms of the numbers of radical prostatectomies, the world's largest prostate cancer center. There is no institution with a similar specialization in Europe. We combine a comfortable atmosphere and the specialization of a small private hospital with the security of multidisciplinary cutting-edge medicine found at the University Medical Center. We are very proud that patients from all over Germany and now also from almost all European countries come to us. More than 98 per cent of the patients treated by us would recommend us to their friends or relatives – one of the most valuable indicators of high satisfaction.

About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

Subscribe

Documents & Links